A074
IMMUNE DYNAMICS IN RESPONSE TO PD-1 BLOCKADE IN MURINE ORAL CAVITY CANCER
Immunotherapy / Systemic Therapy
Katherine C Wai, MD; Lauren S Levine, MD; Iliana Tenvooren, MS; Patrick K Ha, MD; Mekhail Anwar, MD, PhD; Matthew H Spitzer, PhD
University of California San Francisco
A075
BLOOD EOSINOPHIL COUNT MAY PREDICT SEVERE IMMUNE-RELATED ADVERSE EVENTS DUE TO NIVOLUMAB IN RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Yushi Ueki, MD, PhD; Takeshi Takahashi, MD; Ryusuke Shodo, MD, PhD; Keisuke Yamazaki, MD, PhD; Arata Horii, MD, PhD
Department of Otolaryngology Head and Neck Surgery Niigata University Faculty of Medicine
A077
REAL WORLD OUTCOMES IN PATIENTS WITH HNSCC TREATED WITH CHECKPOINT INHIBITION
Sara B Hobday1; Robert M Brody, MD1; Barry A Kriegsman, MD, PhD1; Devraj Basu, MD, PhD, FACS2; Jason Newman, MD, FACS1; Roger B Cohen, MD3; Abigail Doucette4; Lova Sun, MD, MSCE5
1Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, The Wistar Institute, Philadelphia, PA; 3Abramson Cancer Center of the University of Pennsylvania, Philadelphia PA; 4Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA; 5Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA
A078
RACIAL REPRESENTATION IN CLINICAL TRIALS OF IMMUNE CHECKPOINT INHIBITORS IN HEAD AND NECK CANCER
Grace M Amadio, BS1; Anita Sulibhavi, MD2; Olivia Given Costello, MLIS3; Jeffrey C Liu, MD2
1Lewis Katz School of Medicine at Temple University; 2Department of Otolaryngology, Head and Neck Surgery, Temple University, Philadelphia, PA; 3Charles Library, Temple University
A079
COMPUTATIONAL AND IN VITRO EVALUATION OF SHARED IMMUNOGENIC NEOANTIGENS IN ADENOID CYSTIC CARCINOMA
James A Cevallos, MS1; Catherine Y Han, BS2; Fengshen Kuo, PhD3; Jingming Wang, PhD3; Zaineb Nadeem, MS3; Patrick Ha, MD1; Luc Morris, MD, MSc3
1UCSF; 2Weill Cornell Medicine; 3Memorial Sloan Kettering Cancer Center
A080
ONCOLOGIC QUALITY METRICS IN PATIENTS WITH OPERABLE MUCOSAL HEAD AND NECK SQUAMOUS CELL CARCINOMA ENROLLED IN NEOADJUVANT TARGETED THERAPY TRIALS
Marco A Mascarella, MD; Varun Vendra; Mark W Kubik; Shaum Sridharan; Seungwon Kim; Robert L Ferris; Moon J Fenton; James P Ohr; Dan P Zandberg; Umamaheswar Duvvuri
University of Pittsburgh Medical Center
AHNS05
NEUTROPHIL TO LYMPHOCYTE RATIO AND PERIPHERAL BLOOD BIOMARKERS CORRELATE WITH OUTCOMES AMONG PATIENTS WITH RECURRENT METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA AND SALIVARY GLAND CANCER TREATED ON A PHASE II TRIAL OF PEMBROLIZUMAB AND VORINOSTAT
Cassie Pan1; Qian (Vicky) Wu2; Jenna Voutsinas2; Jeffrey J Houlton1; Brittany Barber1; Neal Futran1; Renato G Martins3; Jonathan R Fromm4; Cristina P Rodriguez3
1Department of Otolaryngology, University of Washington, Seattle, WA; 2Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 3Division of Oncology, Department of Medicine, University of Washington, Seattle, WA; 4Department of Laboratory Medicine, University of Washington, Seattle, WA
AHNS09
EFFECT OF PREOPERATIVE IMMUNOTHERAPY ON COMPLICATIONS AFTER HEAD AND NECK SURGERY
Ramez Philips, MD; Angela Alnemri; Adam Luginbuhl, MD; David Cognetti, MD; Joseph Curry, MD
Thomas Jefferson University Hospitals
AHNS Annual Meeting
Held during the Combined Otolaryngology
Spring Meetings (COSM)
April 27-28, 2022
Hyatt Regency Dallas
Dallas, TX